Le Lézard
Classified in: Health
Subject: FDA

Rapid Medical Announces FDA Approval of Novel Temporary Aneurysm Embolization Assist Device


YOKNEAM, Israel, May 7, 2019 /PRNewswire/ -- Rapid Medical, a company focused on the development of next generation neurovascular devices, today announced that its Comaneci device received FDA clearance as a Temporary Coil Embolization Assist Device. The Comaneci is the first and only device in a new category of temporary coil embolization assist devices. 

The Comaneci is the first-ever adjustable, fully-visible aneurysm remodeling device. It acts as a temporary bridge used to aid in the coiling processes while minimizing the risk of coil protrusion or prolapse. Once the coiling procedure is completed the device is removed from the parent artery. It is the only temporary coiling assist device that does not require parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting. Until now the Comaneci have been successfully used in about 3,000 procedures outside the US.

"I am excited about having the Comaneci in the US. It should be a valuable alternative for ruptured and unruptured wide neck aneurysms, typically requiring balloon assistance for coil embolization, since it provides temporary protection of the parent artery during aneurysm coiling without arresting flow," said Peter Kim Nelson, MD, Professor in the Departments of Radiology and Neurosurgery in the New York University School of Medicine and Chief of the Bernard and Irene Schwartz Interventional Neuroradiology Section within the NYU Langone Health system.

"We are extremely pleased by FDA's clearance of the Comaneci device, which will be our first device available in the US.  We want to thank the FDA team for their efforts during the review process to bring it to a successful completion," said Dr. Orit Yaniv, VP of Regulatory Affairs at Rapid Medical.

About Rapid Medical

Rapid Medical is developing game-changing devices for endovascular treatments. Rapid Medical is the maker of TIGERTRIEVER, the first-ever controllable, fully visible stentriever that is designed to treat ischemic stroke patients, and, COMANECI, the first-ever controllable aneurysm neck-bridging device. TIGERTRIEVER and COMANECI are CE marked for use in Europe. More information is available at www.rapid-medical.com.

Contact:
Ronen Eckhouse
+972-72-2503331  
ronen@rapid-medical.com

 

SOURCE Rapid Medical


These press releases may also interest you

at 06:38
Elsevier, a global leader in information analytics specializing in science and health, is making Embase, its biomedical database, available to Research4Life with immediate effect. Elsevier is a founding partner of Research4Life, a public-private...

at 06:35
Sage Therapeutics , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Cowen & Co....

at 06:35
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will present a company overview at...

at 06:35
Epizyme, Inc. , a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2019 financial results. "We began 2020 with...

at 06:30
The "Refractory Epilepsy- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Refractory...

at 06:16
United Therapeutics Corporation and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to the Unity Subcutaneous Delivery System for Remodulin®...



News published on 7 may 2019 at 09:00 and distributed by: